EGFR Mutation Impacts Recurrence in High-Risk Early-Stage Lung Adenocarcinoma in the IASLC Grading System
Author:
Nomura Kotaro1, Aokage Keiju1, Kaminuma Yasunori1, Nakai Tokiko1, Wakabayashi Masashi1, Ikeno Takashi1, Koike Yutaro1, Taki Tetsuro1, Miyoshi Tomohiro1, Tane Kenta1, Samejima Joji1, Ishii Genichiro1, Tsuboi Masahiro1
Affiliation:
1. National Cancer Center Higashi Hospital: Kokuritsu Gan Center Higashi Byoin
Abstract
Abstract
Introduction: The developments of perioperative treatments for patients with high-risk early-stage lung cancer are ongoing, however, real-world data and evidence of clinical significance of genetic aberration is lacking in this population. This study aimed to identify patients with early-stage lung adenocarcinoma at high risk for recurrence based on pathological indicators of poor prognosis, including the International Association for the Study of Lung Cancer (IASLC) grade, and elucidate the prognostic impact of epidermal growth factor receptor mutation (EGFRm) status.
Methods: This retrospective study included 494 consecutive patients who underwent complete resection for pathological stage I lung adenocarcinoma between 2011 and 2016. The patients were evaluated for EGFRm and IASLC grade. Multivariable analysis was used to identify pathological factors for poor prognosis associated with recurrence-free survival (RFS) and overall survival (OS). Patients with any one of these factors were classified into the high-risk group. The prognostic impact of EGFRm was evaluated using RFS, OS, and cumulative recurrence proportion.
Results: Multivariable analysis for RFS and OS revealed that IASLC grade 3, pathological invasion size>2 cm, and presence of lymphovascular invasion were indicators of poor prognosis. EGFRm-positive patients had a higher incidence of all types of recurrence, including central nervous system (CNS) metastasis and distant metastasis in high-risk group, but not in low-risk group.
Conclusions: This study provides evidence that patients with EGFRm-positive stage I lung adenocarcinoma in the high-risk group have an increased risk of recurrence, including CNS metastasis. These findings highlight the need for development of adjuvant treatment in this population.
Publisher
Research Square Platform LLC
Reference21 articles.
1. 1. Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr/today. Accessed 24, August 2022 2. 2. Ettinger DS, Wood DE, Aisner DL (2022) NCCN Guidelines Version 3.2022 Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 24 August 2022 3. 3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (21):3552–3559. doi:10.1200/jco.2007.13.9030 4. 4. Hung JJ, Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC, Chou TY, Hsu WH (2014) Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 32 (22):2357–2364. doi:10.1200/jco.2013.50.1049 5. 5. Travis WD, Brambilla E, Rami-Porta R, Vallières E, Tsuboi M, Rusch V, Goldstraw P (2008) Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol 3 (12):1384–1390. doi:10.1097/JTO.0b013e31818e0d9f
|
|